Liposomes:  a promising carrier for respiratory syncytial virus therapeutics

Sameer Joshi; Swapnil Bawage; Pooja Tiwari; Daniel Kirby; Yvonne Perrie; Vida Dennis; Shree R Singh

doi:10.1080/17425247.2019.1652268

Liposomes: a promising carrier for respiratory syncytial virus therapeutics

Sameer Joshi, Swapnil Bawage, Pooja Tiwari, Daniel Kirby, Yvonne Perrie, Vida Dennis, Shree R Singh

Research output: Contribution to journal › Review article › peer-review

Abstract

Introduction: Human respiratory syncytial virus (RSV) is a common respiratory virus that causes severe lower respiratory tract infection in infants, children and aged adults. Currently, there is no active prophylaxis present in the market for RSV infection; however, there are over a dozen compounds being tested in the laboratory as well as clinical trials. To increase the efficiency and safety of these therapeutics, there is a need for delivery vehicles. Areas covered: Liposomes can be used for delivering anti-RSV agents with the advantage of modulating and eliciting the desired adjuvant effect by the different combination of lipids. This review discusses the promising application of liposome for anti-RSV therapeutics. Expert opinion: Liposomes are attracting attention for delivery of pulmonary therapeutics, since they offer compatibility for delivering drugs, vaccines and other therapeutic molecules. Variation in liposome size and composition gives flexibility for the amount and number of deliverables, whilst targeted delivery with the capability for immunomodulation makes liposomes a promising candidate for RSV therapeutic applications.

Original language	English
Pages (from-to)	969-980
Number of pages	12
Journal	Expert Opinion on Drug Delivery
Volume	16
Issue number	9
DOIs	https://doi.org/10.1080/17425247.2019.1652268
Publication status	Published - 7 Aug 2019

Bibliographical note

This is an Accepted Manuscript of an article published by Taylor & Francis Group in
Expert Opinion on Drug Delivery on 7 Aug 2019, available online at: http://www.tandfonline.com/10.1080/17425247.2019.1652268

Keywords

RSV
drugs
lipids
liposomes
peptides
small molecules

Access to Document

10.1080/17425247.2019.1652268

Liposomes: a promising carrier for respiratory syncytial virus therapeuticsAccepted author manuscript, 993 KB

Cite this

@article{cd7d91f2269e4818b725e102480764fc,

title = "Liposomes: a promising carrier for respiratory syncytial virus therapeutics",

abstract = "Introduction: Human respiratory syncytial virus (RSV) is a common respiratory virus that causes severe lower respiratory tract infection in infants, children and aged adults. Currently, there is no active prophylaxis present in the market for RSV infection; however, there are over a dozen compounds being tested in the laboratory as well as clinical trials. To increase the efficiency and safety of these therapeutics, there is a need for delivery vehicles. Areas covered: Liposomes can be used for delivering anti-RSV agents with the advantage of modulating and eliciting the desired adjuvant effect by the different combination of lipids. This review discusses the promising application of liposome for anti-RSV therapeutics. Expert opinion: Liposomes are attracting attention for delivery of pulmonary therapeutics, since they offer compatibility for delivering drugs, vaccines and other therapeutic molecules. Variation in liposome size and composition gives flexibility for the amount and number of deliverables, whilst targeted delivery with the capability for immunomodulation makes liposomes a promising candidate for RSV therapeutic applications.",

keywords = "RSV, drugs, lipids, liposomes, peptides, small molecules",

author = "Sameer Joshi and Swapnil Bawage and Pooja Tiwari and Daniel Kirby and Yvonne Perrie and Vida Dennis and Singh, {Shree R}",

note = "This is an Accepted Manuscript of an article published by Taylor & Francis Group in Expert Opinion on Drug Delivery on 7 Aug 2019, available online at: http://www.tandfonline.com/10.1080/17425247.2019.1652268 ",

year = "2019",

month = aug,

day = "7",

doi = "10.1080/17425247.2019.1652268",

language = "English",

volume = "16",

pages = "969--980",

journal = "Expert Opinion on Drug Delivery",

issn = "1742-5247",

publisher = "Informa Healthcare",

number = "9",

}

TY - JOUR

T1 - Liposomes

T2 - a promising carrier for respiratory syncytial virus therapeutics

AU - Joshi, Sameer

AU - Bawage, Swapnil

AU - Tiwari, Pooja

AU - Kirby, Daniel

AU - Perrie, Yvonne

AU - Dennis, Vida

AU - Singh, Shree R

N1 - This is an Accepted Manuscript of an article published by Taylor & Francis Group in Expert Opinion on Drug Delivery on 7 Aug 2019, available online at: http://www.tandfonline.com/10.1080/17425247.2019.1652268

PY - 2019/8/7

Y1 - 2019/8/7

N2 - Introduction: Human respiratory syncytial virus (RSV) is a common respiratory virus that causes severe lower respiratory tract infection in infants, children and aged adults. Currently, there is no active prophylaxis present in the market for RSV infection; however, there are over a dozen compounds being tested in the laboratory as well as clinical trials. To increase the efficiency and safety of these therapeutics, there is a need for delivery vehicles. Areas covered: Liposomes can be used for delivering anti-RSV agents with the advantage of modulating and eliciting the desired adjuvant effect by the different combination of lipids. This review discusses the promising application of liposome for anti-RSV therapeutics. Expert opinion: Liposomes are attracting attention for delivery of pulmonary therapeutics, since they offer compatibility for delivering drugs, vaccines and other therapeutic molecules. Variation in liposome size and composition gives flexibility for the amount and number of deliverables, whilst targeted delivery with the capability for immunomodulation makes liposomes a promising candidate for RSV therapeutic applications.

AB - Introduction: Human respiratory syncytial virus (RSV) is a common respiratory virus that causes severe lower respiratory tract infection in infants, children and aged adults. Currently, there is no active prophylaxis present in the market for RSV infection; however, there are over a dozen compounds being tested in the laboratory as well as clinical trials. To increase the efficiency and safety of these therapeutics, there is a need for delivery vehicles. Areas covered: Liposomes can be used for delivering anti-RSV agents with the advantage of modulating and eliciting the desired adjuvant effect by the different combination of lipids. This review discusses the promising application of liposome for anti-RSV therapeutics. Expert opinion: Liposomes are attracting attention for delivery of pulmonary therapeutics, since they offer compatibility for delivering drugs, vaccines and other therapeutic molecules. Variation in liposome size and composition gives flexibility for the amount and number of deliverables, whilst targeted delivery with the capability for immunomodulation makes liposomes a promising candidate for RSV therapeutic applications.

KW - RSV

KW - drugs

KW - lipids

KW - liposomes

KW - peptides

KW - small molecules

UR - https://www.tandfonline.com/doi/abs/10.1080/17425247.2019.1652268?journalCode=iedd20

UR - http://www.scopus.com/inward/record.url?scp=85070510236&partnerID=8YFLogxK

U2 - 10.1080/17425247.2019.1652268

DO - 10.1080/17425247.2019.1652268

M3 - Review article

C2 - 31382795

SN - 1742-5247

VL - 16

SP - 969

EP - 980

JO - Expert Opinion on Drug Delivery

JF - Expert Opinion on Drug Delivery

IS - 9

ER -